Skip to content

ALDEYRA THERAPEUTICS, INC.: 10-Q filed 2025-11-05

What ALDEYRA THERAPEUTICS, INC. reported in its quarterly report filed 2025-11-05 (fiscal Q3 2025): 36 published measures, 98 facts as tagged in accession 0001193125-25-266989.

This filing

Form
10-Q (quarterly report)
Filed
2025-11-05
Fiscal period
fiscal Q3 2025
Accession
0001193125-25-266989 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ALDEYRA THERAPEUTICS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-09-3077,801,012USD
At 2024-12-31104,606,694USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2025-09-3028,556,469USD
At 2024-12-3133,601,823USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-09-3049,244,543USD
At 2025-06-3055,288,142USD
At 2024-12-3171,004,871USD
At 2024-09-3085,095,704USD
At 2024-06-3098,310,339USD
At 2023-12-31119,795,030USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2025-09-3059,340,599USD
At 2024-12-3154,527,092USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-7,688,341USD92
2025-01-01 to 2025-09-30-27,385,154USD273
2024-07-01 to 2024-09-30-15,112,983USD92
2024-01-01 to 2024-09-30-40,042,677USD274

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2025-01-01 to 2025-09-30-28,046,337USD273
2024-01-01 to 2024-09-30-31,171,902USD274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2025-01-01 to 2025-09-301,123,556USD273
2024-01-01 to 2024-09-30-179,201USD274

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2025-01-01 to 2025-09-3031,736,288USD273
2024-01-01 to 2024-09-30-43,351,884USD274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-09-30-477,495,746USD
At 2024-12-31-450,110,592USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2025-07-01 to 2025-09-3060,126,850shares92
2025-01-01 to 2025-09-3060,020,763shares273
2024-07-01 to 2024-09-3059,530,113shares92
2024-01-01 to 2024-09-3059,453,312shares274

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2025-07-01 to 2025-09-3060,126,850shares92
2025-01-01 to 2025-09-3060,020,763shares273
2024-07-01 to 2024-09-3059,530,113shares92
2024-01-01 to 2024-09-3059,453,312shares274

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-0.13USD/shares92
2025-01-01 to 2025-09-30-0.46USD/shares273
2024-07-01 to 2024-09-30-0.25USD/shares92
2024-01-01 to 2024-09-30-0.67USD/shares274

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-0.13USD/shares92
2025-01-01 to 2025-09-30-0.46USD/shares273
2024-07-01 to 2024-09-30-0.25USD/shares92
2024-01-01 to 2024-09-30-0.67USD/shares274

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2025-01-01 to 2025-09-305,001,332USD273
2024-01-01 to 2024-09-306,710,160USD274

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-8,001,132USD92
2025-01-01 to 2025-09-30-28,597,323USD273
2024-07-01 to 2024-09-30-16,137,576USD92
2024-01-01 to 2024-09-30-43,539,248USD274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-09-3077,460,035USD
At 2024-12-31104,072,478USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2025-09-3028,483,933USD
At 2024-12-3118,601,823USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2025-09-3013,423USD
At 2024-12-31180,453USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2025-07-01 to 2025-09-305,430,757USD92
2025-01-01 to 2025-09-3021,359,309USD273
2024-07-01 to 2024-09-3012,441,509USD92
2024-01-01 to 2024-09-3033,594,761USD274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-09-3060,162,773shares
At 2024-12-3159,648,278shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2025-09-3059,340,599USD
At 2024-12-3154,527,092USD
At 2024-09-3068,120,029USD
At 2023-12-31142,823,016USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2025-09-30815USD
At 2024-12-3137,442USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2025-09-30340,977USD
At 2024-12-31266,955USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2025-09-30344,484USD

Long-term debt

Long-term borrowings under this concept, which can include the current portion depending on presentation. It is not total liabilities and may exclude leases and other obligations.

PeriodValueUnitDays
At 2025-09-3015,300,000USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2025-09-306,999,297USD
At 2024-12-3112,118,367USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2025-09-302,162,696USD
At 2024-12-312,921,206USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2025-01-01 to 2025-09-30-27,385,154USD273
2024-01-01 to 2024-09-30-40,042,677USD274

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-7,676,531USD92
2025-01-01 to 2025-09-30-27,421,781USD273
2024-07-01 to 2024-09-30-15,036,785USD92
2024-01-01 to 2024-09-30-39,976,137USD274

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2025-07-01 to 2025-09-302,570,375USD92
2025-01-01 to 2025-09-307,238,014USD273
2024-07-01 to 2024-09-303,696,067USD92
2024-01-01 to 2024-09-309,944,487USD274

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2025-01-01 to 2025-09-30186,877USD273
2024-01-01 to 2024-09-30185,250USD274

Nonoperating interest expense

Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.

PeriodValueUnitDays
2025-07-01 to 2025-09-30475,903USD92
2025-01-01 to 2025-09-301,430,051USD273
2024-07-01 to 2024-09-30479,252USD92
2024-01-01 to 2024-09-301,455,378USD274

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2025-07-01 to 2025-09-30312,791USD92
2025-01-01 to 2025-09-301,212,169USD273
2024-07-01 to 2024-09-301,024,593USD92
2024-01-01 to 2024-09-303,496,571USD274

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2025-01-01 to 2025-09-301,267,250USD273
2024-01-01 to 2024-09-301,329,167USD274

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2025-01-01 to 2025-09-300USD273
2024-01-01 to 2024-09-30-217,261USD274

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2025-01-01 to 2025-09-30-167,030USD273
2024-01-01 to 2024-09-30-1,151,138USD274

Inspect the source

Entity
ALDEYRA THERAPEUTICS, INC. / CIK 0001341235
Captured
2026-09-20T07:54:15.451Z
SEC response SHA-256
71cda24b59474759e40949f545ab949ecdfc2871814e3cf45050931d1c516763

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001341235.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))